Biotech Co.* |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
| | |||
Acologix Inc.* |
Toray Industries Inc. (Japan) |
Acologix got rights to develop and sell Toray's TRK-820 in North America, and co-development rights in Europe |
TRK-820 is a selective kappa opioid receptor agonist that has completed Phase II trials in uremic pruritus; terms of the deal were not disclosed (6/16) |
Adherex |
GlaxoSmithKline |
Adherex licensed GSK's cancer product eniluracil, and GSK got an option to license Adherex's ADH-1 (Exherin), a Phase II cancer compound |
GSK retains options to buy back eniluracil during development; if so, Adherex would be entitled to development and sales milestone payments of up to $120M, plus royalties; if GSK licenses ADH-1, Adherex would receive up-front, development and sales milestone payments of up to $100M, plus double-digit royalties on any sales (7/15) |
Aeres |
Syngenta AG (Switzerland) |
Deal to develop one of Aeres' humanized antibodies |
Terms of the deal were not disclosed; also, Syngenta made an undisclosed payment to Epimmune Inc., which assigned certain parts of its existing deal with Aeres to Syngenta (7/19) |
Alfacell |
The Novartis Institute for Tropical Diseases (Singapore) |
NITD got rights to conduct in vitro testing to evaluate the activity of AC 03-636 in dengue fever |
In vivo studies in animal models potentially could follow; further details on the material transfer agreement were not disclosed (7/21) |
Alnylam |
Sigma-Aldrich Corp. |
Sigma-Aldrich got nonexclusive rights to provide research products and services in RNA interference under Alnylam patents |
The Kreutzer-Limmer patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (7/19) |
Aphios Corp.* |
Bio Research Corp. and Tokyo Supply Ltd. (both of Japan) |
Deal to develop an oral, water- soluble paclitaxel prodrug for cancer |
Terms of the deal were not disclosed (7/19) |
Aptanomics |
Boehringer Ingelheim GmbH (Germany) |
Collaboration on aptamer-based target validation and drug discovery |
Aptanomics will provide aptamers and characterize their binding to therapeutic targets; terms of the deal were not disclosed (8/1) |
Astex |
AstraZeneca plc (UK) |
Collaboration to discover and commercialize small-molecule inhibitors of protein kinase B for use as anticancer agents |
Astex gets $5M up front, research funding and up to $270M in regulatory and sales milestones; it would get double-digit sales royalties, and retains an option to co-promote resulting products in the U.S. (7/27) |
Arrow |
Novartis Pharma AG (Switzerland) |
Collaboration to develop and market Arrow's small-molecule inhibitor A60444 for respiratory syncytial virus |
Arrow gets a $10M up-front payment and up to $217M in milestone payments, as well as royalties on resulting sales; Novartis also gets rights to back-up compounds, and the right of first negotiation on other compounds (6/29) |
Aureus |
Sanofi-Aventis Group (France) |
Sanofi became the first customer for Aureus' AurSCOPE-Ion Channel database |
The deal extends an existing collaboration covering other databases; terms were not disclosed (6/9) |
Avanir |
AstraZeneca plc (UK) |
Collaboration to discover and develop Reverse Cholesterol Transport-enhancing compounds for treating cardiovascular disease |
Avanir gets $10M up front and is eligible for up to $330M in milestone payments, as well as royalties rising from single-digit to low-double-digit rates; AstraZeneca is responsible for costs and development (7/11) |
BioFocus plc |
NV Organon (the Netherlands) |
BioFocus will use its expertise in GPCR drug discovery to generate leads for Organon targets |
The deal followed a screening collaboration between the companies; terms were not disclosed (8/8) |
BioSyntech |
Nicholas Piramal India Ltd. (India) |
NPIL acquired exclusive rights to BioSyntech products in India, Pakistan, Sri Lanka, Bangladesh, Laos, Cambodia, Vietnam and the Philippines |
NPIL is purchasing 7.5M BioSyntech shares at C$0.80 each (US$4.95M in stock) and will own about 17% of the company; they also will explore collaborative opportunities (7/8) |
BioVeris Corp. |
Baxter Healthcare Corp. |
BioVeris licensed rights to a portfolio of vaccine candidates covering multiple diseases |
The vaccines are based on a conjugate technology platform; Baxter is entitled to up-front, milestone and royalty payments (8/11) |
Caliper Life |
Agilent Technologies Inc. |
Agilent got nonexclusive rights to use microfluidics technology for development of clinical diagnostic applications |
Agilent will develop the applications on its platforms; also, Caliper will exclusively supply planar LabChip products to Agilent for five years (7/12) |
Caprion |
Boehringer Ingelheim GmbH (Germany) |
Deal to to identify biomarkers of metabolic and inflammatory disease using Caprion's CellCarta proteomics platform |
Caprion will identify pharmacodynamic markers in plasma following administration of preclinical compounds; terms were not disclosed (7/12) |
Caprion |
Wyeth |
They expanded an existing deal to include two clinical programs under way at Wyeth |
The focus is on discovery and development of protein biomarkers from Phase II trials in asthma and renal-cell carcinoma; terms of the deal were not disclosed (6/28) |
Cell Signaling |
Johnson & Johnson Pharmaceutical Research & Development |
Deal to use CST's PhosphoScan technology to identify phosphorylation sites and biomarker kinase targets |
Terms of the deal were not disclosed (7/11) |
Cellzome Inc.* |
Novartis Pharma AG (Switzerland) |
They expanded a deal under which Cellzome is mapping the protein networks of several signaling pathways |
The additional work will focus on providing more in-depth functional analyses of target candidates and signaling aspects of disease pathways; terms were not disclosed (7/26) |
ChemGenex |
Stragen Pharma SA (Switzerland) |
Collaboration to accelerate the clinical development of ChemGenex's Phase II cancer drug Ceflatonin |
Stragen brings manufacturing and marketing expertise to the deal, and would get 51% of profits in Europe; ChemGenex has product responsibility in North America and the Asia-Pacific region (6/27) |
Chronogen |
Inpharzam Ricerche (Swiss unit of Zambon Group SpA) |
Deal to identify small molecules for treating cardiovascular and metabolic diseases induced by oxidative damage and/or lipid disorders |
Chronogen will screen the Inpharzam library in the deal; further details were not disclosed (7/1) |
Ciphergen |
Quest Diagnostics Inc. |
Deal to develop and sell proteomic diagnostic tests based on Ciphergen's SELDI ProteinChip technology |
Quest purchased 17% of Ciphergen, or 6.2M shares, for $15M; it got a five-year warrant to purchase another 2.2M shares at $3.50 each; Quest also provided a loan of up to $10M that would be forgiven if certain milestones are met(7/22) |
Ciphergen |
Bayer Pharmaceuticals Corp. |
Collaboration to identify biomarkers and develop an assay that may be used in a clinical trial in cancer |
Ciphergen will analyze patient samples from Phase II trials as part of the deal; it is entitled to up-front and milestone payments from Bayer (6/27) |
Codexis Inc.* |
Matrix Laboratories (India) |
Codexis will apply its re- engineering technology to develop a process for an active pharmaceutical ingredient |
Codexis gets R&D funding along with potential milestone payments and royalties on any sales; Matrix gets exclusive rights to the process (6/15) |
CombinatoRx |
HenKan Pharmaceutical Co. (Taiwan) |
HenKan got rights to develop and sell the cancer agent CRx-026 in Taiwan, China and South Korea |
CombinatoRx gets $500,000 up front and up to $23M in development and commercial milestone payments, plus royalties on sales; HenKan also will fund certain Phase II trials (7/18) |
Competitive |
Beckman Coulter Inc. |
Beckman Coulter got a license to a homocysteine assay |
Competitive Technologies gets a license fee and royalties on sales of homocysteine assay products (7/28) |
Conforma |
Sumitomo Pharmaceutical Co. Ltd. (Japan) |
Conforma got exclusive rights in North America and Europe to the cancer drug Amrubicin |
The synthetic anthracycline agent is marked in Japan as Calsed; terms of the deal were not disclosed (6/29) |
Correlogic |
Quest |
Quest got an option to commercialize certain diagnostic tests |
Correlogic received an equity investment; further terms were not disclosed (6/9) |
Cougar |
LEO Pharma |
Cougar got exclusive rights to seocalcitol (EB1089), a synthetic analogue of vitamin D with applications in cancer |
LEO gets an up-front payment and is entitled to milestone and royalty payments (6/28) |
Cypress |
NV Organon (the Netherlands) |
Deal to combine expertise to develop a treatment for obstructive sleep apnea involving mirtazapine-based drugs and regimens |
They initially will share costs; Cypress would have co- commercialization rights in North America, and get royalties on sales elsewhere (6/29) |
Cytomyx |
Wyeth Pharmaceuticals |
Cytomyx got rights to create and market cell lines expressing the ion channel Kv4.3 and four KChIP accessory subunits |
Cytomyx will use the technology in research reagents for use in drug discovery and screening; terms were not disclosed (8/4) |
Depomed Inc. |
Esprit Pharma Inc. |
Esprit got exclusive rights to market Proquin XR in the U.S and Puerto Rico; the product was approved for treating uncomplicated urinary tract infections |
Depomed gets $30M up front and $20M more within 24 months, as well as royalties of 15% to 25%; launch of the extended- release formulation of ciprofloxacin is expected in 4Q:05 (7/28) |
Diversa Corp. |
Merck & Co. Inc. |
They expanded a deal signed in January focused on Diversa's MedEv antibody evolution platform |
Diversa gets an additional up-front payment and research funding, and is entitled to milestone and royalty payments upon successful development of antibodies (6/20) |
Dyax Corp. |
Merck KGaA (Germany) |
Merck got nonexclusive rights to phage display libraries for discovery and development of antibody and peptide drugs |
Dyax gets an up-front license fee, as well as annual maintenance fees and potential milestone and royalty payments; Merck also has an option under which Dyax would perform funded research (8/18) |
Exelixis Inc. |
Helsinn Healthcare SA (Switzerland) |
Helsinn gained rights to develop the Phase III cancer drug XL119 (becatecarin) |
Exelixis gets $4M up front and up to $21M in milestone payments; Helsinn will pay Phase III costs; Exelixis is entitled to royalties and milestones on sales, and retained an option to reacquire rights in the U.S. (6/10) |
Evotec AG |
Procter & Gamble Pharmaceuticals Inc. |
Evotec will provide pharmaceutical discovery and chemical development services to P&G |
The deal follows a 2004 program between them in which Evotec screened for a P&G target; terms were not disclosed (7/25) |
Evotec AG |
Almirall Prodesfarma SA (Spain) |
Evotec will design and synthesize for Almirall drug-like compounds across a range of chemical templates |
Terms of the two-year library synthesis agreement were not disclosed (7/21) |
Fabre-Kramer |
NV Organon (the Netherlands) |
Fabre-Kramer reacquired all rights to the depression drug Gepirone ER, which failed to gain FDA approval in 2004 |
Organon would receive a milestone payment upon FDA approval, and royalties on any sales; Phase III trials are ongoing (6/15) |
Galapagos NV |
Novartis Pharmaceuticals UK Ltd. |
Galapagos' Galadeno unit will design a research program for Novartis for functional assays in human primary cell assays |
Galadeno will get research payments in exchange for providing technology, reagents and support to Novartis (7/6) |
Genaissance |
NV Organon (the Netherlands) |
Deal to apply Genaissance's HAP technology for pharmacogenetic research in clinical trials |
They will look at modulation of the HPA stress axis for treating psychiatric disorders; Genaissance gets license fees and research funding, and has certain rights to develop companion genetic tests (7/18) |
Genedata AG* |
DSM Biologics (the Netherlands) |
DSM Nutritional Products licensed rights to biologic solutions from Genedata |
DSM got rights to the Genedata Phylosopher and Genedata Expressionist technology under undisclosed terms (7/28) |
Genedata AG* |
Novartis Institute for Tropical Diseases (Singapore) |
Collaboration to advance research in infectious and parasitic diseases |
Genedata's Phylosopher technology will serve as a management system for data integration; terms were not disclosed (6/29) |
Generex |
Stallergenes SA (France) |
Deal to design and test Ii-Key/allergen epitope hybrid peptides for treating asthma and allergic reactions |
Generex subsidiary Antigen Express Inc. will work with Stallergenes on the project; terms of the deal were not disclosed (6/22) |
Geron Corp.(GERN) |
Merck & Co. Inc. |
Collaboration and license agreement to develop a cancer vaccine targeting telomerase; Merck also acquired an option to negotiate a deal for Geron's dendritic cell- ased telomerase vaccine that's in Phase I/II trials |
Geron gets an up-front payment and is eligible to receive milestone and royalty payments; Merck also will invest in Geron's next round of financing; Geron got an option payment in the second deal; terms would be negotiated upon exercise of the option (7/18) |
Halozyme |
Baxter Healthcare Corp. |
Baxter exercised its option to market Hylenex in the European Union |
Baxter already had rights in the U.S. to Hylenex, a recombinant human hyaluronidase being developed for use as a spreading agent; terms were not disclosed (8/8) |
Human Genome |
GlaxoSmithKline plc(UK) |
GSK exercised its option to jointly develop and sell HGS-ETR1 (mapatumumab), a drug candidate for cancer |
GSK exercised an option from a 1996 deal on the Phase II product; they will equally share costs going forward and any profits (8/18) |
Human Genome |
GlaxoSmithKline plc (UK) |
GSK exercised its option to jointly develop and sell LymphoStat-B for rheumatoid arthritis and lupus |
The option from the 1996 deal was exercised following Phase II trials; they will equally share costs going forward and any profits (7/7) |
Human |
Agilent Technologies Inc. |
Collaboration to develop a set of metabolome analysis tools for use in drug discovery |
They plan to integrate HMT's biochemical assays with Agilent's capillary electrophoresis and mass spectrometry technology to profile and identify metabolic markers (6/20) |
ImClone |
UCB Group (Belgium) |
Deal to develop and market UCB's CDP-791, an antibody targeting VEGFR-2; the cancer drug is entering Phase II trials |
They will share development costs and worldwide profits; ImClone has commercialization rights in North America, with UCB having such rights in the rest of the world (8/15) |
Indevus |
Schering AG (Germany) |
Indevus licensed U.S. rights to market Nebido, a long- acting injectable testosterone preparation; it is approved in Europe |
Indevus will pay $7.5M up front and $5M upon U.S. approval, and up to $17.5M in regulatory and commercial milestones; Schering also would get a percentage of net sales (7/29) |
Inpharmatica |
Tibotec Pharmaceuticals Ltd. (Belgium; unit of Johnson & Johnson) |
Tibotec will use Inpharmatica's Chematica technologies to study the action of antiviral compounds from Tibotec |
The technology links compounds with putative molecular targets; terms of the deal were not disclosed (8/1) |
Intercell AG |
Sanofi-Pasteur Group (France) |
Sanofi exercised its option on exclusive rights to certain bacterial vaccine antigens |
Intercell gets license, research and success fees of €3M; it is entitled to further milestone payments of up to €20M, as well as royalties on resulting sales (7/1) |
Isis |
Eli Lilly and Co. |
They extended a four-year antisense drug discovery collaboration an additional two years |
Lilly also got rights to another Isis drug, an inhibitor of STAT-3 for cancer; Isis is entitled to milestones and royalties from that product; as part of the extension, Isis converted a $100M loan from Lilly into 2.5M shares of Isis common stock (8/8) |
Ixion |
Q-Med AB (Sweden) |
Ixion transferred the assets and employees related to its oxalate technology to Q-Med |
Ixion received almost all of Q-Med's Ixion stock, $344,000 in cash and $6M in debt forgiveness from its former majority share- holder; Ixion regained its independent status (7/11) |
KeyNeurotek |
Schwarz Pharma AG (Germany) |
Schwarz will use Telomics technology from KeyNeurotek to characterize drug candidates in its urology program |
Terms of the deal were not disclosed (7/14) |
KeyNeurotek |
Bayer Healthcare AG (Germany) |
KeyNeurotek got exclusive rights to the traumatic brain injury compound BAY 38-7271 |
KeyNeurotek will continue development and would market the product; terms of the deal were not disclosed (6/29) |
Labopharm |
Purdue Pharma LP |
Purdue got exclusive rights to market Labopharm's once- daily formulation of the analgesic tramadol in the U.S. |
Labopharm gets $20M up front, up to $40M upon FDA approval and additional payments if sales targets are reached; it also would get royalties of 20% to 25% (8/15) |
MAP |
Elan Corp. plc (Ireland) |
They amended a 2004 deal under which MAP is applying Elan's NanoCrystal technology to certain inhalation therapies |
MAP gets additional rights to use the technology for treating multiple respiratory diseases, including asthma; it covers nebulized delivery of budesonide and combinations of budesonide with beta agonists; terms were not disclosed (7/27) |
Medarex Inc. |
Boehringer Ingelheim GmbH (Germany) |
BI will use Medarex's UltiMAb technology to generate antibodies to disease targets |
Medarex gets technology access fees and could receive additional license fees and milestone payments, as well as royalties on resulting sales (6/14) |
MerLion |
Merck & Co. Inc. |
They are expanding and extending deal to discover and develop drugs derived from natural products chemistry |
The deal was extended two years and expanded to include additional targets; MerLion is entitled to up-front, milestone and royalty payments (7/26) |
Metabasis |
Merck & Co. Inc. |
Deal to develop and market small-molecule drugs to treat various diseases by activation of AMP-activated protein kinase |
Metabasis gets $5M up front and research funding; it also is entitled to milestone and royalty payments, along with a co-promotion option in the U.S.; total payments, excluding royalties, for the first product in the first indication could be $54M (6/27) |
Migenix Inc. |
Schering-Plough Corp. |
Schering-Plough got first rights to negotiate a license to celgosivir (MX-3253), a Phase II product for hepatitis C |
Schering-Plough will supply Pegetron and certain services for Migenix's upcoming Phase II combination study; it will have a limited period to review the data and negotiate a license (7/13) |
Millennium |
Schering-Plough Corp. |
Schering-Plough acquired all rights in the U.S. to the GP IIb/IIIa inhibitor Integrilin; they had been co-promoting the drug in the U.S. |
Millennium gets $35.5M up front and royalties on sales; the minimum royalties in 2006 and 2007 are $85M each year; SP also will pay $45M to $50M to Millennium for existing Integrilin inventories (7/22) |
Napo |
AsiaPharm Group Ltd. (Singapore) |
AsiaPharm got exclusive rights in China to develop and sell products derived from crofelemer for treating diarrhea |
Napo receives an equity investment, and also would get royalty payments from sales of any products in China (6/15) |
Novacea Inc.* |
Pierre Fabre Medicament SA (France) |
Novacea acquired U.S. and Canadian rights to the oral chemotherapeutic agent vinorelbine |
The drug is approved in Europe; Pierre Fabre is entitled to up-front, milestone, manufacturing and royalty payments (7/25) |
Nuevolution |
Schering AG (Germany) |
Nuevolution will use its Chemetics technology to find new leads against targets provided by Schering |
Nuevolution will generate and screen libraries to identify the most potent and drug-like ligands; terms of the deal were not disclosed (6/21) |
Odyssey |
Bristol-Myers Squibb Co. |
Odyssey will profile certain BMS compounds in its cell- based assays |
The goal is to further characterize mechanism of action and pathway activity; terms of the deal were not disclosed (7/14) |
OriGene |
Eisai London Research Laboratories |
Eisai licensed OriGene's FlagArray platform for high- throughput target discovery |
Terms of the deal were not disclosed (8/2) |
OSI |
Unnamed Japanese company |
The pharmaceutical firm got a nonexclusive license to use dipeptidyl peptidase IV inhibitors for treating Type II diabetes and related conditions |
OSI is entitled to up-front, milestone and royalty payments; the deal was made with the OSI diabetes and obesity unit Prosidion (7/7) |
OSI |
Merck & Co. Inc. |
Merck got a nonexclusive license to a patent covering the use of dipeptidyl peptidase IV inhibitors with other antidiabetic agents |
OSI is entitled to up-front, milestone and royalty payments; the deal has made with the OSI diabetes and obesity unit Prosidion (6/30) |
Paion AG |
H. Lundbeck A/S (Denmark) |
Deal to develop and market Paion's Phase III product Desmoteplase for stroke everywhere except the U.S. and Canada |
Paion gets €15M up front and up to €50M in milestones for the the indication of stroke; Paion has co-promotion options, and would get double-digit royalties on sales where Lundbeck has exclusivity (7/11) |
Palatin |
Mallinckrodt |
They extended marketing deal covering Palatin's infection imaging agent, NeutroSpec |
Mallinckrodt gained marketing rights in Europe; its rights now are worldwide; terms of the deal were not disclosed (6/15) |
Paradigm |
Ortho-McNeil Pharmaceuticals Inc. (unit of Johnson & Johnson) |
Ortho licensed rights to Paradigm programs with potential utility in pain and urinary incontinence |
Paradigm gets up-front research payments and is eligible to receive milestone and royalty payments (6/30) |
Paradigm |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Three-year deal under which Paradigm will provide exclusive access to targets in certain central nervous system areas |
Paradigm gets up-front and exclusivity payments, and is entitled to milestones of up to $18M per product, as well as royalties on resulting sales (6/30) |
ParAllele |
Merck & Co. Inc. |
Deal to discover genetic variations applicable to cancer susceptibility, prognosis or response to therapy |
ParAllele will use its genotyping technology to characterize genetic changes in tumor samples identified by Merck; terms of the deal were not disclosed (7/6) |
Pharmacopeia |
Allergan Inc. |
Allergan got rights to angiogenesis-targeting compounds in the field of ophthalmology |
Pharmacopeia gets an up-front payment and may get preclinical and clinical payments, plus milestone and royalty payments (7/12) |
Pharmasset |
Bukwang Pharm. Co. Ltd. (South Korea) |
Pharmasset got certain rights to develop and sell Clevudine (L-FMAU) for treating chronic hepatitis B virus infections |
Pharmasset's rights are in the Americas, Europe and Israel; Bukwang got an option to market the Phase II HBV product Racivir in Korea; terms were not disclosed (6/27) |
Santhera |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Collaboration to develop and market Idebenone (SNT-MC17), a small-molecule drug for treating Friedreich's ataxia |
Santhera gets €5M up front and potential milestone and royalty payments; Takeda gets exclusive rights in Europe; Phase III trials are planned (8/3) |
Sareum |
Almirall Prodesfarma SA (Spain) |
Sareum will provide protein structuredetermination services to accelerate drug discovery research at Almirall |
The goal is to determine how Almirall's drug candidates interact with their target proteins; terms were not disclosed (8/10) |
SeBo GmbH* |
Novartis AG (Switzerland) |
Novartis acquired global rights to an oral phosphate binder for treating elevated serum phosphate levels |
Rights to the Phase I compound include patients with chronic kidney disease or patients already on dialysis; terms of the dealwere not disclosed (8/18) |
7TM Pharma |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
Collaboration to further develop 7TM's program on oral compounds for treating asthma and allergic diseases |
7TM gets an up-front fee, research funding and potential milestone payments, as well as royalties on resulting products; J&J takes over development responsibility (6/8)@ |
Sternberger |
Covance Inc. |
Covance acquired the complete line of antibodies developed by Sternberger |
The deal was made by subsidiary Covance Research Products Inc.; terms of the deal were not disclosed (6/27) |
Structural |
Eli Lilly and Co. |
They extended for three years an April 2003 deal focused on Lilly's drug discovery programs |
SGX is applying its technologies to Lilly drug targets to determine crystal structures and data on target/inhibitor complexes; terms were not disclosed (7/13) |
Velcura |
Nippon Chemiphar Co. Ltd. (Japan) |
Deal to further develop small-molecule therapies for osteoporosis and other bone diseases |
A lead compound already was discovered; the deal pairs Chemiphar's expertise in drug discovery with Velcura's process of growing human bone in tissue culture (8/9) |
ViroLogic |
Schering-Plough Corp. |
ViroLogic will use its HIV resistance testing technology to support discovery and |
ViroLogic will get $4.8M under the multi- year service agreement; the focus is on Schering-Plough's CCR5 receptor antago- nist, vicriviroc (7/6) |
Vitae |
GlaxoSmithKline plc (UK) |
Exclusive deal to develop renin inhibitors for treating hypertension and related cardiovascular disorders |
Vitae gets an up-front payment in cash and an equity investment, committed research funding and potential milestone and royalty payments; pre-commercial payments could total $175M for the lead product; Vitae also retains co-promotion rights in the U.S. (6/20) |
Xencor Inc.* |
Centocor Inc. (unit of Johnson & Johnson) |
Deal to use Xencor technology to create antibody candidates that Centocor will evaluate against an oncology target |
Xencor gets an up-front payment and is eligible to receive additional license fees, as well as milestone and royalty payments (7/18) |
XOMA Ltd. |
Merck & Co. Inc. |
Merck got rights to use bacterial cell expression technology for phage display in the discovery of antibody products |
XOMA gets an access fee along with potential milestone and royalty payments; Merck also got an option to use the technology in manufacturing antibodies, which would entail additional payments to XOMA (6/17) |
Xytis |
Fournier Pharma (France) |
Xytis gained rights to develop and sell Fournier's Anatibant for traumatic brain injury and possibly other indications |
Fournier Pharma retained manufacturing rights to the product, which contains its bradykinin B2 antagonist; further terms were not disclosed (6/13) |
YM |
Kuhnil Pharmaceutical Co. (South Korea) |
Deal to develop YM's TheraCIM- hR3 monoclonal antibody for certain patients with non- mall-cell lung cancer |
Kuhnil will fund Korean development and provide an undisclosed amount of up-front, milestone and royalty payments; further terms were not disclosed (6/15) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
@ News occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | |||
